🚀 VC round data is live in beta, check it out!
Maat Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Maat Pharma and similar public comparables like StemRIM, Cardiff Oncology, Medivir, Genelux and more.
Maat Pharma Overview
About Maat Pharma
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
Founded
N/A
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$121M
Maat Pharma Financials
Maat Pharma reported last 12-month revenue of $9M.
In the same LTM period, Maat Pharma generated had net loss of ($33M).
Revenue (LTM)
Maat Pharma P&L
In the most recent fiscal year, Maat Pharma reported revenue of $4M and EBITDA of ($31M).
Maat Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $9M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 61% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($31M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (819%) | XXX | XXX | XXX |
| EBIT Margin | (381%) | XXX | (884%) | XXX | XXX | XXX |
| Net Profit | ($33M) | XXX | ($34M) | XXX | XXX | XXX |
| Net Margin | (390%) | XXX | (899%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Maat Pharma Stock Performance
Maat Pharma has current market cap of $122M, and enterprise value of $121M.
Market Cap Evolution
Maat Pharma's stock price is $6.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $122M | -0.8% | XXX | XXX | XXX | $-1.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMaat Pharma Valuation Multiples
Maat Pharma trades at 14.1x EV/Revenue multiple, and (3.9x) EV/EBITDA.
EV / Revenue (LTM)
Maat Pharma Financial Valuation Multiples
As of April 19, 2026, Maat Pharma has market cap of $122M and EV of $121M.
Equity research analysts estimate Maat Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maat Pharma has a P/E ratio of (3.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | 14.1x | XXX | 32.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.9x) | XXX | XXX | XXX |
| EV/EBIT | (3.7x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 52.5x | XXX | XXX | XXX |
| P/E | (3.6x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/FCF | (3.1x) | XXX | (4.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Maat Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Maat Pharma Margins & Growth Rates
Maat Pharma's revenue in the last 12 month grew by 185%.
Maat Pharma's rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Maat Pharma's rule of X is 388% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Maat Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 185% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (819%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 43% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 62% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 388% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 83% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 600% | XXX | 854% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 945% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Maat Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Maat Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| StemRIM | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiff Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maat Pharma M&A Activity
Maat Pharma acquired XXX companies to date.
Last acquisition by Maat Pharma was on XXXXXXXX, XXXXX. Maat Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Maat Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMaat Pharma Investment Activity
Maat Pharma invested in XXX companies to date.
Maat Pharma made its latest investment on XXXXXXXX, XXXXX. Maat Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Maat Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Maat Pharma
| Where is Maat Pharma headquartered? | Maat Pharma is headquartered in France. |
| Is Maat Pharma publicly listed? | Yes, Maat Pharma is a public company listed on Euronext Paris. |
| What is the stock symbol of Maat Pharma? | Maat Pharma trades under MAAT ticker. |
| When did Maat Pharma go public? | Maat Pharma went public in 2021. |
| Who are competitors of Maat Pharma? | Maat Pharma main competitors are StemRIM, Cardiff Oncology, Medivir, Genelux. |
| What is the current market cap of Maat Pharma? | Maat Pharma's current market cap is $122M. |
| What is the current revenue of Maat Pharma? | Maat Pharma's last 12 months revenue is $9M. |
| What is the current revenue growth of Maat Pharma? | Maat Pharma revenue growth (NTM/LTM) is 185%. |
| What is the current EV/Revenue multiple of Maat Pharma? | Current revenue multiple of Maat Pharma is 14.1x. |
| Is Maat Pharma profitable? | No, Maat Pharma is not profitable. |
| What is the current net income of Maat Pharma? | Maat Pharma's last 12 months net income is ($33M). |
| What is the current FCF of Maat Pharma? | Maat Pharma's last 12 months FCF is ($39M). |
| What is Maat Pharma's FCF margin? | Maat Pharma's last 12 months FCF margin is (449%). |
| What is the current EV/FCF multiple of Maat Pharma? | Current FCF multiple of Maat Pharma is (3.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.